Adherex Technologies Inc. To Release Global Development Plans For Eniluracil On November 16 Conference Call

Adherex Technologies Inc. (AMEX:ADH)(TSX:AHX), a biopharmaceutical company with a broad portfolio of oncology products under development, today announced that as part of its third quarter 2005 financial results conference call scheduled for November 16, 2005, the Company will release its global development plans for the oncology drug, eniluracil, which was in-licensed from GlaxoSmithKline (GSK) in July 2005. The presentation will include the new understanding of the drug's mechanism of action and the supporting scientific data that will enable the Company to initiate clinical trials this December and pivotal Phase III trials by mid-2007.

Back to news